Flomax CR Tab · DIN 02270102 · 0.4 mg ·
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-15 — choose a marketed DIN from the same-category list.Discontinued February 15, 2024 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-15 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-15 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Flomax CR Tab · DIN 02270102
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2006-06-15
Health Canada: Cancelled post market since 2024-02-15 · brand FLOMAX CR · ATC G04CA02 TAMSULOSIN · form Tablet (extended-release) · route Oral · ingredients TAMSULOSIN HYDROCHLORIDE 0.4 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02270102)
Source record
DIN 02270102: Flomax CR Tab
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000534; group id 969; item number 2301; lccId None; manufacturer id BOE
Source form: None; strength: 0.4mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.6700; ministry $0.1500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02270102
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75550
Therapeutic Notes (formulary)
Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.
Interchangeable products
Apo-Tamsulosin CR Tab · DIN 02362406 · $0.1500
Auro-Tamsulosin CR Tab · DIN 02545179 · $0.1500
Sandoz Tamsulosin CR Tab · DIN 02340208 · $0.1500
Tamsulosin CR Tab · DIN 02427117 · $0.1500
Tamsulosin CR Tab · DIN 02429667 · $0.1500
Teva-Tamsulosin CR Tab · DIN 02368242 · $0.1500
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since February 15, 2024 — choose a marketed DIN from the same-category list.